Novo Nordisk, FDA

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday. Several doses of Novo's GLP-1 therapies such as Wegovy and diabetes drug Ozempic,
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
Ozempic and Wegovy considered ‘available’ after more than two years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years after being declared in shortage by the Food and Drug Administration (FDA).
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as "available" on the U.S. Food and Drug Administration's drug shortage list. The change in status comes nearly six months after Novo Nordisk,
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo’s main Ozempic plant cited for quality lapses by FDA
Novo has been racing to boost supplies of its drugs for obesity and diabetes after initially underestimating demand.
Key Novo Nordisk plant where Wegovy, Ozempic made cited by FDA
A Novo Nordisk production facility in Denmark where semaglutide, the active ingredient in its weight loss and type 2 diabetes medicines Wegovy and Ozempic, are made was cited for several deficiencies during an FDA site inspection in March.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...
Benzinga.com7d
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Plus, with a pipeline that includes blockbuster drugs like Ozempic and Wegovy, Novo Nordisk is making moves in the cardiovascular space, and even eyeing treatments for Alzheimer's and alcohol ...